Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04006522 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

StatusActive, Not Recruiting
PhasePhase 2
Started2019-10-02
View on ClinicalTrials.gov ↗
This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of patients with localized RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to nephrectomy and a second cohort of patients with metastatic RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to treatment with an immune checkpoint inhibitor.

Amendment history 4 changes detected by DataLookout

2026-09-01
Primary completion pushed: 2025-10-07 → 2026-08-06
2026-09-01
Completion pushed: 2026-12-31 → 2027-08-31
2026-04-29
Trial status changed: Recruiting → Active, Not Recruiting
2026-04-29
Enrollment reduced: 55 → 46 participants
Trial Details
NCT Number NCT04006522
Lead Sponsor James Brugarolas
Conditions Renal Cell Carcinoma
Enrollment 46 participants
Start Date 2019-10-02
Primary Completion 2026-08-06 (estimated)
Study Completion 2027-08-31 (estimated)
Updated on ClinicalTrials.gov 2026-08-31